Background. Dysmorphic red blood cells (dRBCs) on urine microscopy have been associated with glomerulonephritis (GN). We assessed the prevalence and ability of dRBCs to differentiate GN from other kidney diseases. Methods. Adult patients with kidney biopsy performed between 2012 and 2015 at a single center who had a concurrent urinalysis were retrospectively studied. The association of !25% dRBCs with the presence of glomerular pathology was assessed. Univariate and multivariate logistic regression were performed on significantly associated variables. Results. The mean age of the 482 eligible subjects was 55 years and 47.7% were female. Overall, 173 (35.9%) had <25% and 76 (15.8%) had !25% urine dRBCs. Kidney biopsies revealed glomerular disease in 372 (77.2%) (GN 46% and non-GN 54%). At the dRBC threshold of !25% used at our center, a sensitivity of 20.4%, specificity of 96.3% and positive predictive value of 94.6% for glomerular disease were observed. In a logistic regression model, urine RBCs [>10 versus 10 (P < 0.001)] but not dRBCs !25% (P ¼ 0.3) independently predicted the presence of GN. A scoring system (0-3) based on hematuria and proteinuria levels revealed the risk for biopsy-proven GN was 15% when the score was 0 compared with 83% when it was 3. Conclusions. The presence of !25% urine dRBCs is specific but not sensitive for GN. In this cohort, the combined hematuria (>10 RBCs/high-power field) and proteinuria performed just as well as dRBCs plus proteinuria to predict underlying GN. A model based on the degree of hematuria and proteinuria found on urinalysis was able to predict the presence of GN.
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I N T R O D U C T I O N
Urinalysis with microscopy remains an essential tool for timely diagnosis and management of kidney diseases [1, 2] . The presence of dysmorphic red blood cells (dRBCs) has been associated with glomerular diseases (GDs) and thus is reported by some laboratories. In 1979, Birch and Fairly initially described the distorted morphology of RBCs seen under phase contrast microscopy that they associated with glomerular bleeding, coining the term dRBC [3, 4] . Phase contrast microscopy offers the best ability to discriminate urinary sediment elements and is felt to be superior to bright field microscopy for this purpose [4] [5] [6] . Up to nine different morphologies of dRBCs have been described in the literature [7] [8] [9] [10] . Of these, acanthocytes seem most specific for GD [8] . A recent report suggested that urinary acanthocytes associate with proliferative lesions on renal biopsies of lupus nephritis patients [11] . However, the exact morphologies used to categorize dRBCs and the number needed to make disease associations has not been standardized, likely impacting its sensitivity and specificity [1] . Depending on the study design and selected population, the clinical cutoff for significant dRBCs in the literature varies between 10% and 90% [12] . Factors that have impacted the interpretation of these studies include the relatively small size, small number of biopsy proven kidney disease entities and sometimes the use of clinically established (rather than biopsy-proven) diagnoses [7, 9, [12] [13] [14] . Our laboratory has used a standard approach to identify dRBCs in any urinalysis with microscopic hematuria since 1998 and reports whether the total exceeds 25% of all RBCs observed. This provided an opportunity to evaluate the clinical utility of dRBCs assessed in a standardized way in a consecutive cohort over many years. In the current study, we retrospectively analyzed the association of dRBCs and renal pathology in a large cohort of patients that had available renal biopsies. Our objectives were to assess the prevalence of dRBCs in common kidney diseases and the factors that determine their presence and to establish whether the presence of dRBCs differentiates between glomerular and nonglomerular processes. Additionally, we investigated whether other elements of a standard urinalysis associated with a pathologic diagnosis of GN.
M A T E R I A L S A N D M E T H O D S

Study design and subjects
This study was approved by the Mayo Clinic Institutional Review Board. All patients who underwent a kidney biopsy between August 2012 and January 2015 at the Mayo Clinic in Rochester, MN, USA were identified using an existing pathology database. All adult patients with a kidney biopsy performed at our institution and with a urinalysis available within 2 weeks prior to the biopsy were identified. Kidney transplant allograft biopsies, pediatric kidney biopsies, those with insufficient tissue to make a definitive diagnosis and patients that declined authorization to use their medical records for research purposes were excluded. Baseline demographics, including age at the time of biopsy, sex and race/ethnicity were retrieved by electronic chart review.
Urinalysis and dRBCs
Urine was collected into a clean, sterile container by random void, midstream or catheterization, depending on the clinical situation. All samples were analyzed in the Mayo Clinic Renal Testing Laboratory within 2 h of collection. Urine chemistries and electrolytes were measured using a Roche Chemistry Autoanalyzer (Cobas c511), while pH and osmolality were assessed using a pH meter and PSI osmometer (Tecan). A 24-h urinary protein excretion was estimated from the protein: osmolality ratio (e24P [15] ). The Mayo Renal Laboratory uses a spot protein:osmolality ratio to estimate the 24-h urinary protein (estimated 24-h protein or e24P) as a part of every urinalysis done, based on previously published data demonstrating that the protein:osmolality ratio is analogous to the protein:creatinine ratio and correlates at least as well with a 24-h protein collection [15, 16] . Since the osmolality and urine protein concentration (not dipstick) are measured on all urinalyses in our laboratory, a protein:osmolality ratio and e24P are available on all standard urinalyses. The unit of this measurement is (mg/L)/(mOsm/kg). Urinary hemoglobin was analyzed by automated dipstick on the IRIS system. Urinalyses were read by trained laboratory personnel blinded to the protocol.
In the Mayo Renal Testing Laboratory workflow, the majority of samples are analyzed unspun using the IRIS imaging system. All images are reviewed and verified before results are reported. Abnormal samples (total protein >100 mg/dL), samples with a cloudy appearance or samples flagged with casts, abnormal cells (e.g. renal tubular epithelial cells) or dRBCs on the IRIS are selected for manual microscopy. By these criteria $ 30% of samples, those that contain any pathologic findings listed above, undergo confirmatory manual microscopy. This approach has been shown to produce an accurate characterization of urine since the IRIS platform can reproducibly detect abnormal sediment in an unspun urine sample regardless of the dilution and concentration of the sample [17] . Manual microscopy is performed by centrifuging 12 mL of urine for 5 min at 2000 g, removing the supernatant and resuspending the sediment in the residual urine (500 mL). Resuspended sediment of 25 ml was placed on a slide for microscopic review of a minimum of 10 fields. The following elements were documented: RBCs, RBC casts, white blood cells (WBCs), WBC casts, renal tubular epithelial cells, renal epithelial cell casts, granular casts, hyaline casts, transitional epithelial cells, fat and crystals. The urinalysis result included in this study was the one that was closest to and preceded the biopsy. We only intended to assess one urinalysis and correlate that with biopsy findings since commonly these patients will have only one close to the time of kidney biopsy.
Hematuria was reported in grades as follows: <3 RBCs/ high-power field (hpf) (normal), 3-10, 11-20, 21-30, 31-40, 41-50, 51-100 and >100. If !3 RBCs/hpf were present, technicians assessed the presence of dRBCs under phase contrast microscopy at Â400 and expressed this as the percentage of all RBCs observed in 10-12 hpf (<25% or !25%). The standard laboratory protocol is to identify mainly acanthocytes and their variants as dRBCs; crenated and ghost cells are specifically excluded (Supplementary Figure S1 ). When necessary, 25 mL of 25% acetic acid was added to the sediment to lyse RBCs and exclude budding yeast. A second technician verified any questionable cases. By these criteria, clinical validation studies in the laboratory in the 1990s established a cutoff of !25% dRBCs as optimal for distinguishing GD.
Kidney biopsy and pathologic examination
The kidney biopsy diagnosis was retrieved from the Mayo Renal Pathology database and verified by manual electronic chart review. All had light microscopy, immunofluorescence and electron microscopy evaluation. Two renal pathologists (S.H.N. and S.S.) reviewed the individual diagnosis to establish three broad renal disease categories: glomerular, vascular and tubulointerstitial. When patients had clear evidence of more than one process, a primary and a secondary diagnosis were reported and those cases were classified as 'dual lesions'. When the pathologic process was glomerular (GD), it was subclassified into glomerulonephritis (GN) versus non-GN. GN was based on the presence of glomerular hypercellularity and/or intracapillary infiltrating inflammatory cells. Examples of typical entities classified in this group included pauci-immune GN and immunoglobulin A nephropathy (IgAN). Otherwise, glomerular involvement was noted as non-GN, including diabetic glomerulosclerosis and membranous nephropathy. Although grouping pauci-immune GN and anti-glomerular basement membrane nephritis with IgAN and other GNs represents multiple different pathological entities, all are proliferative lesions that result in destruction of glomerular structures, and it seems reasonable to group these together in comparison with the nonproliferative nephrotic pathologies. If the written reports were not clear, the pathology slides were retrieved and rereviewed (by S.H.N. and S.S.) to ascertain the diagnosis and classification.
Statistical analysis
Continuous variables were expressed as mean (SD) if they were normally distributed or as median [interquartile range (IQR)] if they were nonnormally distributed. Categorical variables were reported as count (percentage). Logistic regression was used to look at the association between dRBCs !25% and demographics and urinalysis variables (such as urine pH, osmolality and number of RBCs). Variables potentially associated with GN (proteinuria, level of hematuria, dRBCs !25%, creatinine and serum albumin) were assessed using univariable and multivariable logistic regression. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were computed from these data. A P-value <0.05 indicated statistical significance. Statistical analyses were performed using SAS version 9.4 (SAS Institute Cary, NC, USA).
R E S U L T S Patients and urinalysis findings
A total of 482 patients with kidney biopsies and concurrent urinalyses were eligible for this study ( Table 1 ). The mean age was 55 years (SD 17), 230 (47.7%) were female and 421 (87.3%) were white. The median protein:osmolality ratio was 3.5 (mg/ L)/(mOsm/kg) corresponding to an estimated 24-h protein of 2518 mg (IQR 740-6963) [15] and median serum creatinine for the group was 2.0 mg/dL (IQR 1.3-3.3). For the entire cohort, 233 (48.3%) lacked microscopic hematuria (urine RBC < 3/ hpf). Among the remaining 249 (51.7%) with hematuria, 173 (35.9%) had <25% urine dRBCs and 76 (15.8%) had !25% urine dRBCs. RBC casts were noted in 2.7% of the patients.
Findings on kidney biopsy
Overall, 372 (77.2%) had GD by biopsy and 110 (22.8%) had non-GD. Among the GD group, 46% had GN and 54% non-GN. For the entire study group, 32 (6.6%) had vascular disease, 109 (22.6%) had tubulointerstitial disease and 31 (6.4%) had two primary diagnoses ( Figure 1 presents the most common pathologies and their respective degrees of hematuria and the percentage of patients with dRBCs (<25% versus !25%). Overall, patients with GD pathologies were more likely to have hematuria and !25% dRBCs. However, 10% of those with vascular disease (primarily hypertensive arteriolosclerosis) had microscopic hematuria and !25% dRBCs. Among those with tubulointerstitial disease (primarily acute tubular necrosis), 55% had microscopic hematuria but only 2.5% manifested !25% dRBCs.
Variables affecting the presence of dRBCs were not associated with the presence of dRBCs (Supplementary Table S1 ).
Diagnostic performance of dRBCs
The sensitivity, specificity, PPV and NPV of dRBCs for GD were next assessed after excluding biopsies with dual lesions (n ¼ 31) ( Table 3 ). The presence of hematuria (RBCs > 3/hpf) had 62.2% sensitivity and 65.2% specificity of a diagnosis of GD. The presence of !25% dRBCs was less sensitive (20.4%) but highly specific (96.3%) for the presence of any glomerular lesion, with a PPV of 94.6% and an NPV of 27.3%. Next, the additive value of estimated 24-h protein (>1000 mg and >3500 mg) and !25% dRBCs was assessed. The presence of >1000 mg of protein combined with dRBCs !25% led to a sensitivity of 17.1%, specificity of 98.2%, PPV of 96.9% and NPV of 25.9% for a diagnosis of GD. For protein !3500 mg in combination with dRBCs !25%, sensitivity was 9.9%, specificity was 99.1%, PPV was 97.1% and NPV was 25.5% for any form of GD. Table 3 also shows the diagnostic performance values for GD and GN (subcategory of GD) with the degree of proteinuria. The diagnostic performance of different degrees of hematuria and proteinuria is shown in Supplementary Table S3 . Similar results were obtained when the analysis included the patients with dual lesions (data not shown).
Next, models were constructed to determine predictors of the presence of GN on biopsy. The univariate analysis revealed that dRBCs !25% [OR 3.73 (95% CI 2.26-6. Table S2 ). In a multivariate model, only urine RBC level {>10 versus 10 RBCs/hpf [OR 6.67 (95% CI 3.89-11.45), P < 0.001]} was predictive of GN (Table  4 ). This was also noted for RBC levels >50 versus 50 RBCs/ hpf (Supplementary Table S4) .
Based on an analysis of combined hematuria and proteinuria, a scoring system was devised using urinary RBCs (< 3, 3-10 and >10 RBCs/hpf; each gives a score of 0, 1 or 2, respectively) and proteinuria <2 g/day (score of 0) versus >2 g/day (a score of 1). The cutoffs were selected using a receiveroperating characteristic curve. When the total score was 0 (no hematuria or <2 g/day of proteinuria), the probability of the presence of GN was 15%. With a score of 1, the probability of GN was 28%, which increased to 41% with a score of 2, and when the score was 3 (indicating >10 RBCs/hpf and 2 g/day of protein), the likelihood of having GN rose to 83% (P < 0.001). When GD is considered (includes GN and non-GN), having a score of 0 was 49% predictive of GD and having a score of 3 increased the likelihood of having GD to 93% (P < 0.001) (Figure 2 ).
D I S C U S S I O N
Since the early recognition of the clinical relevance of dRBCs in 1979, multiple studies have evaluated the usefulness of this finding on urine microscopy. There have been conflicting results, with some studies showing benefit in recognizing GD [7, 13, 14, 18] and correlation with certain histologic findings on kidney biopsy [11] , whereas others have found it to be of little added benefit or questioned its usefulness [19] [20] [21] . Depending on the definition of dRBC (varied morphologies), the population studied (kidney versus urinary collecting system disease and community versus referral center) and the reference gold standard (biopsy versus clinical diagnosis), the cutoffs of what are considered significant dRBCs vary between 10% and 90% [12, [22] [23] [24] . Additionally, prior studies have not looked specifically into the utility of dRBCs for distinguishing glomerular origin versus other nephron compartments (i.e. the distinction between glomerular versus tubulointerstitial kidney disease) based solely on kidney biopsy as the gold standard, as opposed to urological evaluation for the source of bleeding. In this study, we took advantage of a large cohort of patients with available renal biopsies and a standardized urinalysis with microscopy that included reports of dRBCs (<25%, !25%). In this cohort of biopsy-proven diverse kidney disease entities, we found the presence of significant dRBCs (i.e. !25%) to be a relatively uncommon finding (15.8%), but significantly more common than RBC casts (2.7%). The entities that were found to have significant dRBCs present were pauci-immune GN, IgAN, membranous nephropathy and lupus nephritis. Our study indicates that dRBCs are quite specific for GD compared with other nonglomerular kidney diseases, such as those affecting the interstitial and vascular compartments. The finding of >25% dRBCs of the total RBCs noted in a urine sample offers high specificity and high PPV for a diagnosis of GD or GN, which improved when proteinuria was considered. In univariate models, hematuria and dRBCs !25% were both significant predictors of GN. However, in the multivariate regression analysis that included proteinuria, only hematuria (RBCs >10/hpf) remained statistically significant as a predictor of GN. This is perhaps not surprising among this group of patients with a high pretest probability of parenchymal renal disease (i.e. warranted a renal biopsy), since hematuria was more sensitive (but less specific) than dRBCs for GD. In a population that included other nonrenal causes of hematuria (e.g. bladder lesions), dRBCs might perform better than RBCs, even when combined with proteinuria.
We devised a scoring system for predicting the presence of GN on biopsy, based on the optimal cutoff points for both proteinuria (2 g/day) and hematuria (<3, 3-10 and >10 RBCs/hpf) that had the best predictive power for GN. In this cohort, patients with a score of 0 (hematuria <3 RBCs/hpf and proteinuria <2 g/ day) had a 15% chance of having GN. The risk of GN continued to increase with each point until a score of 3 (>10 RBCs/hpf and >2 g/day), where the risk of GN rose to 83%. Importantly, this model would apply to a cohort of patients that met clinical criteria for a parenchymal renal biopsy.
In this study, urine osmolality and pH were investigated regarding their association with dRBCs. Others have found in vitro assessment of urine RBCs in hypotonic urine resulted in hypochromic cells devoid of hemoglobin, or so-called ghost cells [25] . In another study that exposed RBCs in vitro to osmotic and enzymatic environment in an attempt to replicate the nephron milieu, no changes typical of dRBCs were found. However, when osmotically challenged RBCs were exposed to a hemolytic environment, characteristics of dRBCs were evident by light and electron microscopy [26] . Based on our cohort, we found that age at the time of biopsy, urine pH and predicted 24-h urine protein did not affect the presence of dRBCs. A urinary catheter source of urine did not affect the presence of dRBCs, contrary to common perception. Additionally, urine osmolality was marginally associated with an increased presence of dRBCs, with questionable clinical significance. The finding of a higher RBC level (11-50 versus <11 and >50 versus <11 RBCs/hpf) on urinalysis was the variable most likely to predict having significant dRBCs [OR 6.5 (95% CI 3.58-11.8), P ¼ 0.003 and OR 7.8 (95% CI 3.93-15.7), P < 0.001, respectively], a finding that was previously noted [13] . Our laboratory defines dRBCs as mainly those that are ring form (donut shaped) with protrusions (blebs), and their variations. These are the most specific for GD [8, 27] , as there exists other forms reported in the literature that are neither sufficiently sensitive nor specific [7, 8, 28] .
The main strength of this study is that all 482 subjects had biopsy-proven kidney disease, and the pathology was verified by two expert pathologists. It is the largest report in the literature on the association of dRBCs with GD. The scoring system that we devised will allow practitioners to predict the presence of GN, and its potential benefit comes from the readily available details of the urinalysis (proteinuria and hematuria).
Our study also has some limitations. The results reflect the experience of a tertiary referral center with a dedicated renal laboratory having >20 years of experience identifying dRBCs. Results might differ in other settings where the assessment of dRBCs is not standardized. Although automated identification of dRBCs (and other sediment elements such as casts) may become feasible and even standard in the future, the process in our laboratory currently involves automated screening followed by manual microscopy. Using this workflow, our study indicates that dRBCs are quite specific for GD and also carry a high PPV. It is also important to interpret all laboratory findings, including dRBCs, together with associated clinical features. However, the data in the study provide a stronger rationale for investing the effort to detect dRBCs in a standardized fashion for all urinalyses from patients in whom a diagnosis of GN is being entertained. Importantly, the cohort in the current study was entirely a group of patients with a clinically indicated kidney biopsy. The utility of dRBCs versus RBCs and proteinuria might differ in a population that also included patients with urologic causes of hematuria. However, it is important to note that true ascertainment of the origin of hematuria cannot be made with a high degree of confidence without a kidney biopsy. This was one issue with prior studies that have considered the clinical diagnosis of certain glomerular entities without kidney biopsy. Another issue is that we did not have patients with dRBCs who underwent a urologic investigation (e.g. stones, tumor and others along the urogenital tract). We have aimed in this study to investigate glomerular versus nonglomerular parenchymal kidney disease and not urologic versus nonurologic entities. However, given the ability of dRBCs, based on our study, to establish with certainty the presence of GD versus tubular or vascular entities, we hypothesize that it would be unlikely that inclusion of urologic disease entities would have changed our findings, although this would need to be verified in future studies using our methodology. Finally, we did not independently verify the performance of our predictive model in a second cohort.
The presence of !25% dRBCs by urine microscopy is very specific but not sensitive for GN. In this cohort with clinical suspicion of kidney disease that warranted kidney biopsy, combined hematuria (>10 RBCs/hpf) and proteinuria performed just as well as dRBCs plus proteinuria to predict underlying GN. A model based on the degree of hematuria and proteinuria found on urinalysis was able to predict the presence of GN.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http://ndt.oxford journals.org. 
